Regeneron announces adjuvant Libtayo significantly improves DFS after surgery in high-risk CSCC in phase 3 trial: Tarrytown, New York Wednesday, January 15, 2025, 11:00 Hrs [IST] ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare ...

Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline ...

Calidi Biotherapeutics, a clinical-stage biotechnology company, disclosed on January 8, 2025, its entry into a Placement Agency Agreement with Ladenburg Thalmann & Co. Inc. The agreement pertains to ...

Latine individuals in the US face higher morbidity and mortality in skin cancer outcomes despite lower lifetime risk.

Epithelial tissues are in constant interaction with their environment. Maintaining their functionality requires dynamic ...